What Causes High
Triglycerides (TGs)?


Risk Factors That Contribute to High TGs
and Poor Lipid Profiles1

Some risk factors can be changed, and some can’t.

There are many factors that can lead to high TG levels, including

  • Genetics: If you have family members with high TGs or other imbalances in their lipid profiles, you may also experience lipid problems.
  • Poor diet: A diet that is high in saturated fat and sugar can increase the cholesterol and free fatty acids in your blood; a diet in which more than 60% of the calories are from carbohydrates may increase TGs.
  • Poor glucose control: The body’s ability to manage sugars and fats are closely connected. Insulin resistance is linked to higher TG levels.
  • Belly fat: Excess fat around your middle (central obesity) can release chemicals that make it harder for your body to maintain healthy lipid levels.
  • Not enough exercise: The activity of HDL (good) cholesterol is increased by chemicals in muscle tissue. Without exercise, your muscles can become and your HDL levels can drop.

As you can see, many of these health risks are interconnected. A poor diet and too little exercise can make you gain weight. Extra weight makes it harder to control diabetes. Risk factors add up.

The good news is that making healthy lifestyle changes can benefit you. Click here to see how.

 

Reference: 1. National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluations, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III—Final Report. NIH Publication No.02-5215. September 2002.


   

INDICATIONS

Primary Hypercholesterolemia and Mixed Dyslipidemia: ANTARA® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.

Hypertriglyceridemia: ANTARA® is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (eg, >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.

Important limitations of use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.

IMPORTANT SAFETY INFORMATION

ANTARA® is contraindicated in patients with severe renal impairment; active liver disease, including unexplained persistent liver function abnormalities; preexisting gallbladder disease; nursing mothers; and hypersensitivity to fenofibric acid, choline fenofibrate or fenofibrate.

The effect of ANTARA® on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.

Fibrates increase the risk for myopathy and are associated with rhabdomyolysis. The risks for myopathy and rhabdomyolysis are increased when fibrates are co-administered with a statin, particularly in the elderly and in patients with diabetes, renal failure, or hypothyroidism. The combined use of fibrates and statins should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk.

Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness. Discontinue ANTARA® if myopathy/myositis is suspected or diagnosed or if CPK levels are markedly elevated.

Fenofibrate at doses equivalent to 90 mg ANTARA® per day can increase serum transaminases. Monitor liver function regularly and discontinue treatment if enzyme levels persist above 3 times the normal limit.

Fenofibrate can reversibly elevate serum creatinine. Monitor renal function in patients with renal impairment.

Fenofibrate may lead to cholelithiasis. Discontinue ANTARA® if gallstones are found.

ANTARA® can potentiate the activity of oral anticoagulants. Monitoring and dosage adjustment of anticoagulants as needed are recommended.

Other precautions include pancreatitis, hematologic changes, hypersensitivity reactions, and venothromboembolic events.

The most common adverse reactions (>2% and ≥1% greater than placebo) are abnormal liver function tests, increased AST, increased ALT, increased CPK, and rhinitis.

This Web site and the information contained herein is intended for use by US residents only.